The MMRF Blog - Multiple Myeloma Research Foundation

The MMRF Blog

Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

Richardson PG, Jagannath S, Moreau P, Jakubowiak AJ, Raab MS, Facon T, Vij R, White D, Reece DE, Benboubker L, Zonder J, Tsao LC, Anderson KC, Bleickardt E, Singhal AK, Lonial S; 1703 study investigators. Lancet Haematol. 2015 Dec;2(12):e516-27. doi: 10.1016/S2352-3026(15)00197-0. Epub 2015 Nov 16. PMID: 26686406 [PubMed - in process] READ MORE

Posted: January 28, 2016

Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers.

Harshman SW, Canella A, Ciarlariello PD, Agarwal K, Branson OE, Rocci A, Cordero H, Phelps MA, Hade EM, Dubovsky JA, Palumbo A, Rosko A, Byrd JC, Hofmeister CC, Benson DM Jr, Paulaitis ME, Freitas MA, Pichiorri F. J Proteomics. 2016 Jan 13. pii: S1874-3919(15)30214-1. doi: 10.1016/j.jprot.2015.12.016. [Epub ahead of print] PMID: 26775013 [PubMed - as supplied by publisher] READ MORE

Posted: January 28, 2016

Exclusive Q&A with MMRF Board member, Dr. Ken Anderson

What should patients know about the three recent drug approvals in multiple myeloma? The three recent approvals are a continuation of amazing progress in this disease. Ninlaro (ixazomib) is the first oral proteasome inhibitor (it belongs to the same class as ... READ MORE

Posted: December 15, 2015

Page 38 of 87« First...102030...3637383940...506070...Last »